新辅助化疗后间隔减瘤术中加入腹腔热灌注化疗(HIPEC)治疗上皮性卵巢癌的成本效果
基于决策分析模型,从支付方角度比较间隔减瘤术(ICS)与ICS+HIPEC治疗III期上皮性卵巢癌的成本效果。
要点
- ICS+HIPEC的增量成本效果比为2436美元/QALY。
- 造口回纳概率及二次减瘤术中HIPEC使用在一元敏感分析中未显著影响成本效果。
核心结论
- 在新辅助化疗后,ICS+HIPEC对III期上皮性卵巢癌构成具有成本效果的治疗策略。
研究设计与样本
- 决策分析成本效果模型,从支付方角度比较间隔减瘤术(ICS)与ICS+HIPEC两种手术管理策略,成本以2017年美元计,主要结局为增量成本效果比(ICER),以美元/QALY表示。
- 模型假定每组25%的患者后续接受二次减瘤术,ICS组届时可接受HIPEC。
- 生存与造口率来自已发表研究,成本来自Medicare数据、已发表研究及一家学术医院的财务部门,效用值基于既往卵巢癌治疗的时间权衡研究,两组生活质量无差异。
主要发现
- ICS组成本为78,849美元,ICS+HIPEC组为79,954美元。
- ICS+HIPEC相比ICS的ICER为2436美元/QALY。
- 一元敏感分析中,造口回纳概率及二次减瘤术中HIPEC使用未实质性影响ICS+HIPEC的成本效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A recent randomized controlled trial demonstrated an overall survival benefit to the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to neoadjuvant chemotherapy (NACT) for stage III epithelial ovarian cancer (EOC). The objective of the current study was to quantify the cost-effectiveness of HIPEC in this setting. METHODS: A decision analytic cost-effectiveness model was designed from a payer perspective to compare 2 surgical management strategies for EOC: (1) interval cytoreductive surgery (ICS); (2) ICS + HIPEC. Overall survival and ostomy rates with HIPEC were modeled from published studies. We assumed that 25% of each arm would later undergo secondary cytoreductive surgery, with the ICS arm eligible for HIPEC at that time. Costs were obtained from Medicare data, published studies, and the financial department of an academic hospital. Quality of life was not different between the arms; we assigned utilities based on a prior time-trade off study of ovarian cancer treatment. A Monte Carlo probabilistic sensitivity analysis was performed in the base case; primary outcome was the incremental cost-effectiveness ratio (ICER), expressed in 2017 US Dollars/quality-adjusted life years (QALYs). RESULTS: ICS was the least costly strategy at $78,849, compared to ICS + HIPEC at $79,954. ICS + HIPEC was more effective than ICS (2.9 QALYs versus 2.45 QALYs for ICS). ICS + HIPEC was highly cost-effective, with an ICER of $2436/QALY compared to ICS. In one-way sensitivity analyses, probability of ostomy reversal and use of HIPEC at secondary cytoreduction did not substantially impact the cost-effectiveness of ICS + HIPEC. CONCLUSION: ICS + HIPEC constitutes cost-effective management of stage III EOC when NACT is performed.
引用
- Lim SL, Havrilesky LJ, Habib AS, et al. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy. Gynecol Oncol. 2019. PMID: 30718126. doi:10.1016/j.ygyno.2019.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。